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Several advances in large data set collection and processing have the potential to provide
a wave of new insights and improvements in the use of radiation therapy for cancer
treatment. The era of electronic health records, genomics, and improving information
technology resources creates the opportunity to leverage these developments to create
a learning healthcare system that can rapidly deliver informative clinical evidence. By
merging concepts from comparative effectiveness research with the tools and analytic
approaches of “big data,” it is hoped that this union will accelerate discovery, improve
evidence for decision making, and increase the availability of highly relevant, personalized
information. This combination offers the potential to provide data and analysis that can
be leveraged for ultra-personalized medicine and high-quality, cutting-edge radiation
therapy.
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INTRODUCTION
A classical tenet of evidence-based medicine is that the gold standard evidence to evaluate any inter-
vention is a prospective, phase III randomized controlled trial (RCT) that is appropriately powered,
hasmature follow-up, and valid statistical analysis. This principle is emphasized particularly strongly
in oncology, where the stakes are high in terms of risks of cancer mortality, morbidity from cancer
treatment, and the financial toxicity of high-technology treatments.
In an ideal world, evidence from relevant RCTs would be available for each potential medical
intervention with data applicable to each patient seen in the oncology clinic. However, as any
clinician knows, this evidence is not available in the real world, and there are numerous chal-
lenges with this approach. The availability of an informative, practice-defining RCT requires that
the researchers design the study with the end in mind: including patient selection, dosing, and
other important treatment details, timing, potential therapeutic gain, number of subjects, and
representation of important subgroups. RCTs often require a long time to design, conduct, and
mature data, and so even well-designed studies can take decades to report meaningful results, at
which time, the question asked could no longer be relevant due to other advances or trends in
the diagnosis and treatment of cancer. Another significant problem with cancer RCTs is that the
results of well-designed trials are commonly not applicable to patients seen in the clinic, given
potential differences between patients enrolled in RCTs, who are required to meet strict eligibility
criteria, and patients seen in real-world clinics, who may have a complex health history and myriad
comorbidities.
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Comparative effectiveness research (CER) has set out to
overcome many of these weaknesses through mathematical
modeling and simulation with inputs from reported scientific
literature. One goal of CER is to provide evidence for medical
intervention at the population level, something that clinical trials
with strict inclusion and exclusion criteria could never do. Over
the past decade, the validation and acceptance of CER in the US
has made substantial gains (1).
Over the same time period, the collection of medical data has
increased exponentially. With electronic medical records (EMR),
patient databases, and genomic/proteomic data collection,
we literally have more information than we know what to do
with. These are examples of big data. Thankfully, many of the
techniques used to store, synthesize, and interpret information
of this scale have already been created and are being used
commercially. NASA, the NSA, Google, Yahoo, Amazon, and
Netflix, each have developed techniques to funnel oceans of
information into usable packets that can predict the actions or
interests of groups or single subjects (2).
Although the use of big data in healthcare research remains in
its infancy, it has the potential to change the landscape of cancer
care (2–5), and the integration of big data techniques and cancer
therapy is an exciting arena for aspiring entrepreneurs (6, 7).
This article aims to review the future role of big data in cancer
care, specifically addressing its application to CER.
BIG DATA
Big data have a relatively loose definition to date, but generally
it refers to amounts of information too large for human analysis.
This includes data sets around 1012–1018 bytes (8). These are
massive data sets; on the order of number of grains of sand on
the earth (9).
Data this big is inherently heterogeneous. Consider the EMR
as an example. Within a single patient’s EMR, there can be labora-
tory values, diagnostic reports, radiologic image sequences (every
pixel), and clinical notes full of dictation errors and misspellings.
In general, the information in big data sets can be grouped into
structured data (numerical laboratory values or CPT codes) and
unstructured data (a physician’s clinical impression text). It is not
incorrect to view healthcare big data as a massive clinical database
like the Farmington database. However, as discussed below, big
data is hardly limited to EMR input (10).
One important difference between “traditional” research and
big data-based research is that traditional research is hypothesis
driven (2). This means that a research program first involves
formulating a question before designing an experiment to answer
that question. On the other hand, big data research may instead
be data driven: those methods may first be applied to the data
itself to identify potential causal relationships. This can result in
a list of associations with varying degrees of correlation that can
then be further evaluated. In this way, big data analysis may start
the research process before identifying the important questions.
Big data analytic techniques include data mining and machine
learning (8), which are distinct from traditional methods of CER
and offer potential alternative approaches to leveraging large data
resources.
WEAKNESSES
As with any modeling technique, the validity of the results is only
as good as the validity of the initial data. The strength of big data
is in its volume, but its weakness is in its vast heterogeneity. Data
can be missing information, non-interpretable, stored in different
locations, or conflicting. As one entrepreneur in cancer big data
research put it, “EMR data sucks” (7). As an example, consider
the inaccuracy and incompleteness of the family history in a
hospital EMR. Improving the availability of big data exchanges and
repositories for oncology research can only be achieved through
alignment of many sectors of the health care system, which may
be particularly challenging in distributed and partitioned health
systems such as in the US (11). Furthermore, it is important that
big data be collected and analyzed carefully to ensure that the
evidence reflects the heterogeneity and complexity of the patient
population (12).
Conducting big data research requires experience in several
advanced analysis techniques that did not exist a decade ago,
not to mention the new vocabularies that come with them (2).
Realistically speaking, it is impractical for physicians to gain
expertise in these techniques and they will need the assistance of
public health and computer science experts, not to mention the
computational hardware capable of such demanding processing
and mathematical modeling (13, 14). Nonetheless, knowledge of
these techniques is critical not only for researchers but also for
physicians attempting to interpret the resulting publications. In
order to realize the potential of a learning health system, a large
number of analysts and researchers will need training in big data
analytics and health care information technology (8).
Another hurdle for big data in cancer care is the own-
ership of the data. Although an estimated 91% of patients
would permit their personal health information be shared for
medical research (15), the collection and management of the
data will not be performed by patients, and there will likely
need to be integration of data management companies in
big data research (8). Privacy is another important consider-
ation that can limit the development of big data research in
health care (11), since the potential for data breaches could
harm patients and prevent health system participation in big
data exchanges due to fear of data security compromises. The
role that informed consent documents and institutional review
boards (IRBs) should play to protect patient rights in big data
research is unclear but will likely be defined in the com-
ing years.
Because the application of big data predictive analytic meth-
ods to guide health care decisions raises concerns regarding the
validity of the predictive algorithms and methods, it is impor-
tant that attention be focused on validating predictive mod-
els. Clinical application of big data analytics requires trust in
these methodologies on the part of clinicians, with commen-
surate efforts to evaluate the performance of decision support
tools and information provided by big data in health care. As
a result, predictive analytic models using big data to guide
health care choices must be developed and executed in a trans-
parent and replicable way with validation in real-world condi-
tions (16).
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INTEGRATION OF BIG DATA WITH CER:
OPPORTUNITIES FOR RADIATION
ONCOLOGY
The concept of a learning health care system focuses on contin-
uous re-evaluation of healthcare in order to develop and apply
evidence that leads to improved outcomes through a constant
focus on delivering the right treatment to the right patient (8). The
Institute of Medicine Report on the Learning Healthcare System
recommended the development of a health care information tech-
nology infrastructure that could facilitate a learning health care
system to improve health outcomes and reduce health care costs
(17). The era of big data provides opportunities to leverage diverse
sources of information to improve the effectiveness of radiation
therapy (18). The creation of large-volume data exchanges and
repositories that permit rapid pooling, synthesis, and analysis of
data can accelerate discovery in radiation oncology, as well as
other areas of clinical oncology (18).
Big data analytic approaches, such asmachine learning and data
mining, could potentially identify causal relationships between
cancer therapies and clinical outcomes. CER methods can syner-
gize with big data discoveries by providing an analytic approach
to rapidly and effectively validate observations identified using
big data analytics. CER methods, such as observational research
studies or pragmatic trials, can be applied to the data available
in exchanges and registries, or conducted prospectively through
large networks in a learning health system, to validate big data
observations. Since CER methods are designed to directly com-
pare the benefits and harms of all medical alternatives, and to
deliver evidence that is relevant to decision-makers, the CER
framework is useful for providing data that clinicians and other
stakeholders are more likely to trust than big data analytics.
CER methods can be applied to create real-time decision support
resources using data from large exchanges. It can also leverage
the infrastructure of a learning health system to identify sites and
participants for pragmatic trials tomore efficiently test hypotheses
(8). It should be noted that existing claims data sets and other
resources used for oncology CER are relatively small compared
to data sets used outside of health care research, and barely
pass the threshold to be considered “big data” (8). The existing
databases available for CER in radiation oncology are limited in
size and data quality and have several important limitations, as
described by Jagsi and colleagues (19). The availability of more
and “better” data, and the synthesis of big data analytics and
CERmethods, would providemore opportunities for high-impact
oncology research.
For radiation oncology, in particular, the combination of big
data and CER has the potential to contribute to major advances
toward optimizing patient outcomes. Wang has articulated a
vision for the “big-data clinical trial (BCT)” (20), which may hold
promise for accelerating innovation and improved outcomes for
radiation oncology. BCTs would be conducted in a large popula-
tion of patients, providing data that can be evaluated for insights
regarding the effectiveness of therapies in subgroups, the influence
of comorbidities or other factors, and even the identification of
unexpected potential causal relationships using big data analytics
(20). A traditional RCT could then be conducted to evaluate
and potentially validate specific findings observed in a BCT (20).
Alternatively, the research process could involve the opposite
approach: evaluating the findings of a RCT within subgroups
excluded from the trial using a BCT.
For example, one may envision potentially using BCTs to eval-
uate the effectiveness of radiation dose escalation, concurrent
chemotherapy, androgen deprivation, or advanced technologies
in different subgroups of patients receiving radiation therapy.
Such a BCT would provide the opportunity for the establishment
of external validity for clinical trial findings in patients other-
wise excluded from RCTs or in the context of a secular trend in
oncology that is hypothesized to influence outcomes. On the other
hand, big data analytics such as machine learning could identify
novel candidate causal relationships that could then be evaluated
with CER methods such as observational cohort studies using
large data exchanges. Particularly in the era of cancer genomics,
one may envision leveraging large data repositories with detailed
radiation therapy data and genomic profiles of tumor and nor-
mal tissue samples in order to better understand predictors of
tumor control and risk of normal tissue injury, providing radia-
tion oncologists the opportunity to potentially offer personalized
dose prescriptions improving tumor control and reducing toxicity.
In this way, big data could help answer important questions in
radiation oncology that have been previously unanswerable.
Radiation oncology presents special challenges for the creation
of large data exchanges for useful big data studies. In addition to
dose–volume information from radiation therapy plans, the use
of big data analytics can only be successfully applied if all relevant
data elements are available. The potential list of important param-
eters includes diagnostic imaging to include the target volumes
and proximity of normal tissue structures, detailed information
from the radiation treatment plan, image-guidance data, patient
comorbidities, patient demographic data, tumor staging informa-
tion, concurrent chemotherapy and/or hormone therapy, detailed
analyses of tumor specimens, and normal tissue samples. The
relationship between diagnostic image sets (pre-treatment, during
image guidance, and in follow-up) and therapeutic radiotherapy
has led to the storage of a vast amount of data that could serve
multiple purposes, including identifying areas at risk of disease
progression or toxicity if analyzed appropriately. Big data analyses
can only be useful if all potentially available data are available for
analysis using machine learning or other approaches to identify
potential causal relationships for further evaluation. The potential
is profound, but the realization of this vision is complicated and
may be too ambitious to be achieved. The currently available
databases for big data and CER in radiation oncology are not
adequate to support such a lofty program of ground-breaking
discovery (19).
FUTURE DIRECTIONS FOR BIG DATA AND
CER
Several groups have invested significant effort and money into
the use of big data in cancer care (5–7). The National Institute of
Health has created a “big data to knowledge” initiative (BD2K)
(5), in an effort to better define and standardize the analysis of
big data in health care. Additionally, there are several start-up
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companies forming with the aim of big data health research, some
of which receive contributions from Google and other companies
(7). There are multiple cohorts currently collecting data via EMR
for the purpose of big data analysis (21).
Patient reported outcomes (PROs) are an ideal arena for big
data research techniques and are being weighed more and more
heavily as time goes on. These data sets consist of a mixture of
structured and unstructured data of various utilities. Big data
techniques can be utilized to synthesize these large, complex data
sets into comprehensible and actionable items in cancer care (22).
Another new arena for big data research is genomic tumor
analysis. The tumor genome continues to expand and the het-
erogeneity within tumors is extraordinary. Several commercial
assays exist for breast and prostate cancer tissue analysis with
many more on the way for other solid tumors. These assays utilize
tissue microarrays and evaluate for genes predictive of cancer
phenotype. The future of genomic analysis includes genome-wide
tumor sequencing, and in some tumors it is already underway
(23, 24). This would involve base pair sequencing on the order of
billions.
When paired with clinical outcomes, these DNA sequences
offer an ideal input for big data analysis. These results would be
limited in their application if not for CER. CER could be utilized
to predict the utility and cost-effectiveness of such a resource-
consuming test prior to widespread adoption. This technique also
has the potential to apply towhole transcriptomeRNA sequencing
(25), deep phenotyping (26), proteomics (27), and radiogenomics
(the study of tumor genetics and their association with response
to radiotherapy) (28). Future assays will likely have the ability
to incorporate normal patient and tumor DNA, RNA, protein,
and phenotype into a single assay that could be analyzed via big
data and predictive of utility through CER. The overall trend
toward increasing use of genomic assays in oncology may in fact
support the development of big data resources, since the storage
and analysis of genomic information requires information tech-
nology infrastructure for the secure handling of massive amounts
of data.
Perhaps the most exciting possibility for big data and CER in
cancer care is the idea of a “rapid learning health system” (3). This
idea involves the rapid and real-time analysis of various decisions
and their respective utility for a single patient. As an exam-
ple, consider a middle-aged man with low-risk prostate cancer
weighing his options: active surveillance, radical prostatectomy,
brachytherapy, or external beam radiotherapy. The rapid learning
health system has the potential to analyze his EMR and compare
his health history and preferences to other patients in the data
set who have chosen each of the options and offer an optimized
therapy choice for that patient based on his preferences and his
expected risks and gains. Biopsy genomic analysis could also be
incorporated to define patient-specific tumor control probabilities
for each therapy, and incorporate these data into the optimization.
Surgeon or radiation oncologist-specific factors could beweighted
accordingly based on who was performing the procedure. This
would provide real-time, real-life decision analysis for individu-
alized patients: ultra-personalized medicine.
One example of the application of a big data system to facilitate
cancer research is North Carolina’s Integrated Cancer Informa-
tion and Surveillance System (ICISS) (12). This ICISS was devel-
oped with state-level support to serve the mission of improving
outcomes through a learning health system focused on improv-
ing outcomes for cancer patients. The ICISS researchers have
developed a population-based data set that can be queried to
evaluate outcomes, with the appropriate information technology
support and environment to facilitate research to improved can-
cer outcomes. Details of the ICISS may be used as an example
for other organizations, considering implementing similar large-
scale programs aimed at creating a big data infrastructure to
improve outcomes for cancer patients (http://iciss.unc.edu) (12).
In addition, other large health data networks outside of oncology,
such as the National Patient-Centered Clinical Research Net-
work and the National Institute of Health’s Health Care Systems
Research Collaboratory Distributed Research Network, can be
used as roadmaps for developing the information technology
systems to foster big data research in radiation oncology (21).
The development of an information technology infrastructure
to support secure data exchange and foster high-impact cancer
research should be considered a priority in the movement toward
realizing the vision of an effective learning health system (3).
In the current era of cost-conscious medicine and third-party
payers, will big data research carry enough weight to justify pay-
ment for an intervention over the status quo? This is a question
that is unlikely to be answered immediately or within the next
5 years, but there is much enthusiasm and potential in this line
of inquiry. As big data research expands into cancer care, it will
be deeply rooted in money and politics (29), and will serve as
an opportunity for start-up companies and entrepreneurs (7).
Regardless, the addition of CER to big data will serve to project
long-term outcomes and costs for patients with cancer, which will
be of value in discussion with payers. And along these same lines,
it will be important to the overall health system that researchers
remember to critically evaluate big data andCER findings in order
to establish that the information provided by big data and CER is
valuable and helpful to patients and providers (29).
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